These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26943915)

  • 1. Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.
    Cheng H; Xie Z; Jones WP; Wei XT; Liu Z; Wang D; Kulp SK; Wang J; Coss CC; Chen CS; Marcucci G; Garzon R; Covey JM; Phelps MA; Chan KK
    AAPS J; 2016 May; 18(3):737-45. PubMed ID: 26943915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
    Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
    Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry.
    Ebbel EN; Leymarie N; Schiavo S; Sharma S; Gevorkian S; Hersch S; Matson WR; Costello CE
    Anal Biochem; 2010 Apr; 399(2):152-61. PubMed ID: 20074541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
    Gu R; Liu T; Zhu X; Gan H; Wu Z; Li J; Zheng Y; Dou G; Meng Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1000():181-6. PubMed ID: 26245362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
    Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
    Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
    Collier KA; Valencia H; Newton H; Hade EM; Sborov DW; Cavaliere R; Poi M; Phelps MA; Liva SG; Coss CC; Wang J; Khountham S; Monk P; Shapiro CL; Piekarz R; Hofmeister CC; Welling DB; Mortazavi A
    Cancer Chemother Pharmacol; 2021 May; 87(5):599-611. PubMed ID: 33492438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dispositional enantioselectivity of indobufen in rat and mouse.
    Strolin Benedetti M; Moro E; Frigerio E; Jannuzzo MG; Roncucci R; Caldwell J
    Biochem Pharmacol; 1990 Oct; 40(8):1719-23. PubMed ID: 2242009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of a novel histone deacetylase inhibitor, cyclo{(2S)-2-amino-8-[(aminocarbonyl)hydrazono] decanoyl-1-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl} (SD-2007), and its metabolic conversion to apicidin after intravenous injection and oral administration in rats.
    Shin BS; Bulitta JB; Hong DK; Kim HY; Kim MK; Choi Y; Lee JB; Hwang SW; Lee MH; Yoo SD
    Chemotherapy; 2011; 57(3):259-67. PubMed ID: 21597290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling.
    Shin BS; Bulitta JB; Balthasar JP; Kim M; Choi Y; Yoo SD
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):465-75. PubMed ID: 21069337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice.
    Otaegui D; Rodríguez-Gascón A; Zubia A; Cossío FP; Pedraz JL
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):153-9. PubMed ID: 19002463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics, tissue distribution and excretion studies of a novel anti-candidal agent-thiosemicarbazide derivative of isoniazid (TSC-INH) by validated UPLC-MS/MS assay.
    Iqbal M; Ezzeldin E; Bhat MA; Raish M; Al-Rashood KA
    J Pharm Biomed Anal; 2016 Jan; 117():109-17. PubMed ID: 26355768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of HS270, a new histone deacetylase inhibitor, in rat plasma by LC-MS/MS--application to a preclinical pharmacokinetic study.
    Zhong GP; Chen JY; Bi HC; Qin XL; Dai CL; Liu J; Chen X; Zeng GX; Huang ZY; Huang M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov; 879(30):3452-8. PubMed ID: 21983196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enantioselective separation and determination of miconazole in rat plasma by chiral LC-MS/MS: application in a stereoselective pharmacokinetic study.
    Du Y; Luo L; Sun S; Jiang Z; Guo X
    Anal Bioanal Chem; 2017 Nov; 409(27):6315-6323. PubMed ID: 28852798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate.
    Fonsi M; Fiore F; Jones P; Kinzel O; Laufer R; Rowley M; Monteagudo E
    Xenobiotica; 2009 Oct; 39(10):722-37. PubMed ID: 19569735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry.
    Saradhi UV; Gupta SV; Chiu M; Wang J; Ling Y; Liu Z; Newman DJ; Covey JM; Kinghorn AD; Marcucci G; Lucas DM; Grever MR; Phelps MA; Chan KK
    AAPS J; 2011 Sep; 13(3):347-56. PubMed ID: 21499689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry.
    Zuo L; Sun Z; Wang Z; Du S; Kong X; Li L; Yang J; Kang J; Zhang X
    J Pharm Biomed Anal; 2016 Nov; 131():246-255. PubMed ID: 27611096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the pharmacokinetics and metabolism of a novel histone deacetylase inhibitor, KBH-A40, in rats.
    Oh SJ; Lee K; Ryu J; Yu HE; Han G; Park SK; Kang JS; Kim HM; Kim YC
    Xenobiotica; 2011 Feb; 41(2):155-63. PubMed ID: 21070143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.